Structure, Function, and Warning Claims on Gummy Supplement Labels: A Compliance Framework for Manufacturers

Why Gummy Labels Are a Higher-Risk Compliance Surface Than Capsules or Tablets

When most supplement manufacturers think about label compliance, they think about the Supplement Facts panel, net quantity statements, and ingredient declarations. Those are critical, but for gummy manufacturers, the label presents an additional layer of risk that is almost entirely format-specific. Gummies are a food-form delivery system. They look like candy, taste like candy, and are marketed directly to consumers who may not read fine print the way a pharmacist would. That reality creates regulatory tension — and FDA has noticed.

Under 21 CFR Part 101 and the Dietary Supplement Health and Education Act of 1994 (DSHEA), dietary supplement labels must meet both food labeling requirements and supplement-specific requirements simultaneously. For gummy products, this dual obligation is especially demanding because the format blurs the line between confection and supplement. FDA investigators reviewing a gummy label are asking two questions at once: Does this meet dietary supplement labeling law? And does this meet food labeling law? Your label must survive both inquiries.

Beyond the regulatory structure, gummy labels are also more likely to carry bold marketing claims — "supports immunity," "promotes calm," "boosts energy" — because the format lends itself to consumer-friendly branding. Each one of those phrases triggers a compliance obligation under DSHEA. If your QA team is not reviewing label copy with the same rigor it applies to batch records and water activity logs, you have an unmanaged compliance gap sitting in your print files.

Structure/Function Claims: What You Can Say, What You Cannot, and What Requires a Disclaimer

Structure/function claims are the statements on your gummy label or packaging that describe how a nutrient or dietary ingredient affects the structure or function of the human body. These are the most common type of claim on gummy supplement labels, and they are also the most frequently misused. Examples include statements like "supports healthy sleep cycles," "promotes cardiovascular health," or "helps maintain normal blood sugar levels already within the normal range." Each of these is permissible under DSHEA — but only when specific conditions are met.

First, the claim must be truthful and not misleading. FDA does not pre-approve structure/function claims, but the agency evaluates them under a standard of competent and reliable scientific evidence. That means your internal substantiation file — the documentation you maintain to support each claim — must exist before the label goes to print, not after an FDA inquiry arrives. For gummy products specifically, this means your substantiation must account for the finished-product form. A structure/function claim backed by clinical research on a capsule delivery form may not automatically transfer to your gummy if bioavailability is materially different. Your QA team and legal counsel should assess this on a claim-by-claim basis.

Second, if you make a structure/function claim on a dietary supplement label, you are required under 21 CFR 101.93 to notify FDA within 30 days of first marketing the product with that claim, and you must include the mandatory disclaimer. The disclaimer must appear on the label in a box, in boldface type, and must read: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." For gummy products sold in pouches, stand-up bags, or compact containers, fitting this disclaimer legibly can be a physical design challenge — but it is not optional. Shrinking it below the required point size or burying it on an inside panel is a labeling violation.

There are also claim categories you must avoid entirely on dietary supplement labels, regardless of format:

• Disease claims: Any statement that implies your gummy prevents, treats, mitigates, or cures a disease converts your product into an unapproved drug under FDA law. "Reduces inflammation associated with arthritis" is a disease claim. "Supports a healthy inflammatory response" may be permissible as a structure/function claim if properly substantiated and disclaimed.
• Implied drug claims: Language like "clinically proven," "pharmaceutical-grade formula," or references to specific disease biomarkers can imply drug efficacy and draw FDA scrutiny.
• Absolute claims without substantiation: Statements like "guaranteed to boost energy" or "the most effective gummy for focus" create both substantiation and FTC advertising compliance issues simultaneously.

Net Quantity, Serving Size, and the Gummy-Specific Formatting Problem

One of the most common label compliance failures in gummy supplements is not about claims at all — it is about basic formatting errors in the principal display panel and information panel. Net quantity of contents, serving size declaration, and the relationship between the two are areas where gummy manufacturers consistently make errors that would not occur with conventional tablet or capsule products.

Under 21 CFR 101.105, the net quantity of contents must appear on the principal display panel in a type size based on the area of the panel, stated in both metric and inch/pound units as applicable. For gummies sold by count — "60 gummies" for example — this is straightforward. But many gummy products also have a weight on the label, and that weight must be accurate to within the allowable slack-fill tolerances. Because gummies are hygroscopic — they absorb or release moisture depending on storage conditions — the actual weight of your product at time of purchase may differ from the declared weight at time of manufacture. This is not just a consumer protection issue; it is a labeling compliance issue under FDA rules and a potential misbranding trigger.

Serving size for gummies must be declared in a household measure that is meaningful to consumers. For most gummies, this is a piece count — "2 gummies" or "1 gummy." The serving size you declare on the Supplement Facts panel must match what is stated elsewhere on the label. If your front panel says "take 2 daily" but your Supplement Facts panel declares a serving size of 1 gummy, you have a label inconsistency that both FDA and retail buyers will flag. Additionally, the number of servings per container must be accurately calculated and declared. If your gummy count varies by ±3 pieces per bottle due to fill variability on your depositing line, your label needs to reflect the minimum count you reliably deliver, or you need to tighten your fill controls through process validation under 21 CFR Part 111.

Key formatting requirements that gummy manufacturers frequently under-review include:

• Minimum type size requirements: The net quantity statement must meet size thresholds based on the principal display panel area. Gummy products in small stand-up pouches are often non-compliant here.
• Location requirements: Net quantity must appear in the bottom 30% of the principal display panel. Design teams frequently override this for aesthetic reasons.
• Metric equivalents: Weight and volume declarations require metric expression. Count-based products like gummies are exempt from the metric requirement for count itself, but any weight claim must still comply.
• Serving size rounding rules: FDA has specific rounding rules for nutrient quantities in the Supplement Facts panel. Rounding vitamin D from 24.8 mcg to 25 mcg may seem trivial, but systematic rounding patterns across all nutrients can create a panel that materially misrepresents your formula.

Identity Statement, Ingredient Declaration, and Allergen Labeling for Gummies

Every dietary supplement label must include a statement of identity — the common or usual name of the product. For gummy supplements, this statement typically reads something like "Dietary Supplement" and may include the form descriptor "Gummies" or "Chewable Gummies." This statement must appear on the principal display panel in a type size reasonably related to the most prominent printed matter on the panel. It cannot be buried, and it cannot be replaced with a brand name or marketing tagline that does not identify the product category.

The ingredient list for gummy supplements is where many facilities run into problems because gummies require a significantly longer list of functional and processing ingredients than capsules or tablets. Your base gelling agent — whether that is bovine or porcine gelatin, or fish gelatin, or a pectin-carrageenan system for vegan products — must be declared. Sweeteners including sugar, glucose syrup, tapioca syrup, or alternative sweeteners must be listed. Acidulants like citric acid or malic acid, coating agents, natural and artificial flavors, colorants (whether FD&C certified colors or natural colorants like annatto or spirulina), and any added functional ingredients must all appear in the ingredient list in descending order by predominance, as required under 21 CFR 101.4.

Allergen labeling is a particularly high-risk area for gummy manufacturers. Under the Food Allergen Labeling and Consumer Protection Act (FALCPA) as amended by the FASTER Act of 2021, the nine major food allergens — milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, soybeans, and sesame — must be declared on the label either in the ingredient list using common names or in a separate "Contains" statement. Gelatin derived from fish is a potential allergen trigger. Certain gummy flavor systems and natural colorants sourced from facilities that also process tree nuts or sesame can create undeclared allergen risks. Your label review process must include cross-referencing your full bill of materials against allergen declarations on every supplier certificate of analysis, and your allergen control program under your GMP system must be reflected in your label copy.

For gummies manufactured with pectin-based formulations targeting vegan or halal certifications, be aware that certification marks on the label create implied claims that your supply chain must be able to substantiate. If your pectin supplier changes their processing aid or you switch gelatin sources mid-production year, your label certifications may be invalidated without a formal change control review. This is a 21 CFR Part 111 change control requirement as much as it is a labeling issue.

Label Review SOPs and the Connection to GMP Compliance

A label compliance failure is ultimately a GMP failure. Under 21 CFR Part 111, dietary supplement manufacturers are required to establish specifications for their labels, review label copy before use, and maintain records of label receipt, examination, and disposition. This means your label review is not a marketing function — it is a quality function, and it must be documented in your quality system with the same rigor as your batch record review or your raw material release procedures.

Your label review SOP should require at minimum a cross-functional sign-off that includes QA, regulatory, and operations perspectives. QA reviews the label for compliance with 21 CFR Part 101 and DSHEA. Regulatory or legal counsel reviews structure/function claims against the substantiation file and confirms the FDA 30-day notification has been submitted. Operations confirms that the net quantity, serving size, and serving count are consistent with your validated fill weights and your gummy piece count specifications. Without this cross-functional review, errors move from the design file to the print run to the finished product label without correction.

Label version control is another area where GMP programs at gummy facilities frequently break down. When you update a formula — changing from a gelatin base to a pectin base, modifying a flavoring system, or adding a new functional ingredient — your label must be updated to reflect those changes. A formal change control procedure must link formula changes to label review triggers. If your production floor is running Batch 2025-144 with a revised formula but your label inventory still reflects the prior version, you have a misbranded product and a 21 CFR Part 111 recordkeeping failure simultaneously.

Finally, consider the retail and e-commerce compliance layer. Amazon, Walmart, and major retail buyers increasingly require label compliance documentation as part of product onboarding. Amazon's supplement listing requirements include Supplement Facts panel images, structure/function claim substantiation, and allergen declarations that match the physical label. A label that was compliant when you launched two years ago may now be out of alignment with a revised formula, an updated serving size, or a regulatory guidance update. Annual label audits — conducted internally or with a GMP consultant familiar with gummy-specific requirements — are a practical safeguard against both FDA enforcement exposure and retail account risk.